If You Invested in Contineum Therapeutics (CTNM)

Contineum Therapeutics, Inc. (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet medical need. According to the company’s public disclosures, Contineum is advancing an internally developed pipeline with multiple drug candidates in clinical trials, centered on diseases such as idiopathic pulmonary fibrosis, multiple sclerosis, chronic pain and major depressive disorder.

Core focus and therapeutic areas

Contineum describes itself as “pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications.” Its programs are designed as oral small molecules, which the company highlights as a key feature of its approach. The pipeline is built around targets and mechanisms relevant to inflammatory and fibrotic diseases and neurological conditions, with the goal of addressing areas where existing treatment options are limited.

Key clinical programs

The company’s disclosures emphasize two main drug candidates:

• PIPE-791 – Described as an LPA1 receptor antagonist and a “novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 (LPA1) receptor.” Contineum reports that PIPE-791 is in clinical development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS) and chronic pain. Phase 1b positron emission tomography (PET) work has been used to assess pharmacokinetics and receptor occupancy in healthy volunteers and patients, and the company has outlined plans for a global Phase 2 clinical trial in IPF.
• PIPE-307 – Described as a selective inhibitor of the muscarinic type 1 (M1) receptor. Contineum states that PIPE-307 is in clinical development for relapsing-remitting multiple sclerosis (RRMS) and major depressive disorder (MDD). The company has conducted a Phase 2 VISTA trial in RRMS and notes that a separate Phase 2 trial of PIPE-307/JNJ-89495120 in MDD is being conducted under a global license and development agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company.

Pipeline characteristics

Across its communications, Contineum highlights that its programs are internally discovered or internally developed small molecules. The company reports that PIPE-791 has demonstrated high brain receptor occupancy in a Phase 1b PET trial, with a pharmacokinetic relationship between exposure and LPA1 receptor occupancy in healthy volunteers and progressive multiple sclerosis patients. It also notes that PIPE-791 is being evaluated in an exploratory Phase 1b trial in patients with chronic osteoarthritis pain and chronic lower back pain.

For PIPE-307, Contineum has conducted a randomized, double-blind, placebo-controlled, multi-center proof-of-concept Phase 2 trial (VISTA) in RRMS, evaluating safety and efficacy with clinical and imaging endpoints. In a topline update, the company reported that PIPE-307 demonstrated an acceptable safety and tolerability profile but did not meet prespecified primary or secondary efficacy endpoints in that study.

Idiopathic pulmonary fibrosis and IPF trial design

In an 8-K filing, Contineum describes the design of its planned global Phase 2 clinical trial of PIPE-791 in idiopathic pulmonary fibrosis. The trial is characterized as a 26-week, international, randomized, dose-ranging, double-blind, placebo-controlled Phase 2 study evaluating once-daily dosing of PIPE-791 in IPF patients. The company states that the trial is designed to assess safety and tolerability, as well as efficacy measured by the change from baseline in absolute forced vital capacity (FVC) at week 26. Contineum notes that the trial design and launch strategy were informed by regulatory engagement and completed Phase 1 clinical trials.

Multiple sclerosis and chronic pain development

Contineum’s disclosures indicate that PIPE-791 is being developed not only for IPF but also for progressive multiple sclerosis and chronic pain. The company has described a Phase 1b PET trial including progressive multiple sclerosis patients and has referenced plans for a Phase 2 clinical trial in progressive multiple sclerosis, as well as an exploratory Phase 1b chronic pain trial in patients with chronic osteoarthritis pain and chronic lower back pain. In separate updates, Contineum has noted decisions to defer or postpone certain development activities in order to prioritize its IPF program, while continuing exploratory work in chronic pain.

For PIPE-307, Contineum reports that it is in clinical development for relapsing-remitting multiple sclerosis and major depressive disorder. The company has highlighted that, under a global license and development agreement, Janssen Pharmaceutica NV is responsible for developing PIPE-307 for indications other than RRMS, and that Janssen has initiated a Phase 2 trial (Moonlight-1) of PIPE-307/JNJ-89495120 as monotherapy in adults with major depressive disorder.

Corporate and capital markets profile

Contineum Therapeutics, Inc. is incorporated in Delaware and lists its Class A common stock on The Nasdaq Global Market (also referenced as the Nasdaq Global Select Market) under the trading symbol CTNM, as disclosed in multiple Form 8-K filings. The company identifies itself as a clinical-stage biopharmaceutical issuer and has used both at-the-market offerings and underwritten public offerings of Class A common stock to fund operations and clinical development plans.

In a December 2025 Form 8-K, Contineum reported entering into an underwriting agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC, acting as representatives of the underwriters, for an upsized public offering of shares of its Class A common stock under an effective shelf registration statement on Form S-3. The company also references prior at-the-market offerings that generated proceeds used to support its research and development activities.

Regulatory and reporting framework

As a U.S. public company, Contineum files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), including Forms 8-K that describe material events such as clinical data readouts, financing transactions, and shareholder meeting results. These filings confirm that the company’s Class A common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and traded under the symbol CTNM on Nasdaq.

Risk considerations highlighted by the company

In its press releases and SEC filings, Contineum emphasizes that it is heavily dependent on the success of PIPE-791 and PIPE-307, both of which are in early stages of clinical development. The company notes that results from earlier preclinical studies and clinical trials may not be predictive of future outcomes, that regulatory review timelines and outcomes are uncertain, and that unexpected adverse side effects or inadequate efficacy could limit development, regulatory approval or commercialization of its drug candidates. It also highlights reliance on third parties to conduct clinical trials and, in the case of PIPE-307, reliance on Janssen Pharmaceutica NV under a global license and development agreement.

Summary

Overall, Contineum Therapeutics, Inc. presents itself as a clinical-stage biopharmaceutical company centered on NI&I indications, with a pipeline of oral small molecule candidates. Its lead programs, PIPE-791 and PIPE-307, target conditions such as idiopathic pulmonary fibrosis, multiple sclerosis, chronic pain and major depressive disorder. The company’s public communications underscore ongoing clinical trials, collaboration with a large pharmaceutical partner for PIPE-307, and the use of capital markets transactions to support its research and development strategy.